{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T04:52:22Z","timestamp":1791348742837,"version":"4.3.1"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2022,7,20]],"date-time":"2022-07-20T00:00:00Z","timestamp":1658275200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,7,20]],"date-time":"2022-07-20T00:00:00Z","timestamp":1658275200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100015661","name":"UCB Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015661","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Ther"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1007\/s40120-022-00383-3","type":"journal-article","created":{"date-parts":[[2022,7,20]],"date-time":"2022-07-20T17:02:58Z","timestamp":1658336578000},"page":"1535-1551","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Physician-Reported Perspectives on Myasthenia Gravis in the United States: A Real-World Survey"],"prefix":"10.1007","volume":"11","author":[{"given":"Milada","family":"Mahic","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali M.","family":"Bozorg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan J.","family":"DeCourcy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keisha J.","family":"Golden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregor A.","family":"Gibson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian F.","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Ting","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tyler J.","family":"Story","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Scowcroft","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,7,20]]},"reference":[{"issue":"1","key":"383_CR1","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1186\/s12883-019-1573-2","volume":"19","author":"ED Bacci","year":"2019","unstructured":"Bacci ED, Coyne KS, Poon JL, Harris L, Boscoe AN. Understanding side effects of therapy for myasthenia gravis and their impact on daily life. BMC Neurol. 2019;19(1):335.","journal-title":"BMC Neurol"},{"key":"383_CR2","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2020.553626","volume":"11","author":"P Szczudlik","year":"2020","unstructured":"Szczudlik P, Sobieszczuk E, Szyluk B, Lipowska M, Kubiszewska J, Kostera-Pruszczyk A. Determinants of quality of life in myasthenia gravis patients. Front Neurol. 2020;11: 553626.","journal-title":"Front Neurol"},{"issue":"1","key":"383_CR3","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/s41572-019-0079-y","volume":"5","author":"NE Gilhus","year":"2019","unstructured":"Gilhus NE, Tzartos S, Evoli A, Palace J, Burns TM, Verschuuren J. Myasthenia gravis. Nat Rev Dis Primers. 2019;5(1):30.","journal-title":"Nat Rev Dis Primers"},{"issue":"1","key":"383_CR4","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/1750-1172-2-44","volume":"2","author":"VC Juel","year":"2007","unstructured":"Juel VC, Massey JM. Myasthenia gravis. Orphanet J Rare Dis. 2007;2(1):44.","journal-title":"Orphanet J Rare Dis"},{"issue":"8","key":"383_CR5","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1007\/s00415-016-8045-z","volume":"263","author":"N Melzer","year":"2016","unstructured":"Melzer N, Ruck T, Fuhr P, Gold R, Hohlfeld R, Marx A, et al. Clinical features, pathogenesis, and treatment of myasthenia gravis: a supplement to the Guidelines of the German Neurological Society. J Neurol. 2016;263(8):1473\u201394.","journal-title":"J Neurol"},{"issue":"1","key":"383_CR6","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1111\/nyas.13522","volume":"1412","author":"JF Howard Jr","year":"2018","unstructured":"Howard JF Jr. Myasthenia gravis: the role of complement at the neuromuscular junction. Ann N Y Acad Sci. 2018;1412(1):113\u201328.","journal-title":"Ann N Y Acad Sci"},{"issue":"1","key":"383_CR7","doi-asserted-by":"publisher","first-page":"7","DOI":"10.25122\/jml-2020-0145","volume":"14","author":"AM Bubuioc","year":"2021","unstructured":"Bubuioc AM, Kudebayeva A, Turuspekova S, Lisnic V, Leone MA. The epidemiology of myasthenia gravis. J Med Life. 2021;14(1):7\u201316.","journal-title":"J Med Life"},{"issue":"10","key":"383_CR8","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/S1474-4422(15)00145-3","volume":"14","author":"NE Gilhus","year":"2015","unstructured":"Gilhus NE, Verschuuren JJ. Myasthenia gravis: subgroup classification and therapeutic strategies. Lancet Neurol. 2015;14(10):1023\u201336.","journal-title":"Lancet Neurol"},{"issue":"7","key":"383_CR9","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2020-048198","volume":"11","author":"S Berrih-Aknin","year":"2021","unstructured":"Berrih-Aknin S, Claeys KG, Law N, Mantegazza R, Murai H, Sacc\u00e0 F, et al. Patient-reported impact of myasthenia gravis in the real world: protocol for a digital observational study (MyRealWorld MG). BMJ Open. 2021;11(7): e048198.","journal-title":"BMJ Open"},{"key":"383_CR10","first-page":"5","volume":"2021","author":"M Mahic","year":"2021","unstructured":"Mahic M, Zaremba P, Rudnik J, Bozorg A, Dolin P. Currently used therapies for myasthenia gravis do not provide adequate disease control for all patients: a retrospective analysis of United States claims data. Am Assoc Neuromusc Electrodiagn Med. 2021;2021:5.","journal-title":"Am Assoc Neuromusc Electrodiagn Med"},{"issue":"6","key":"383_CR11","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1002\/mus.26695","volume":"60","author":"G Cutter","year":"2019","unstructured":"Cutter G, Xin H, Aban I, Burns TM, Allman PH, Farzaneh-Far R, et al. Cross-sectional analysis of the Myasthenia Gravis Patient Registry: disability and treatment. Muscle Nerve. 2019;60(6):707\u201315.","journal-title":"Muscle Nerve"},{"key":"383_CR12","doi-asserted-by":"publisher","first-page":"175628561774913","DOI":"10.1177\/1756285617749134","volume":"11","author":"R Mantegazza","year":"2018","unstructured":"Mantegazza R, Antozzi C. When myasthenia gravis is deemed refractory: clinical signposts and treatment strategies. Ther Adv Neurol Disord. 2018;11:1756285617749134.","journal-title":"Ther Adv Neurol Disord"},{"key":"383_CR13","doi-asserted-by":"publisher","first-page":"175628641983224","DOI":"10.1177\/1756286419832242","volume":"12","author":"C Schneider-Gold","year":"2019","unstructured":"Schneider-Gold C, Hagenacker T, Melzer N, Ruck T. Understanding the burden of refractory myasthenia gravis. Ther Adv Neurol Disord. 2019;12:1756286419832242.","journal-title":"Ther Adv Neurol Disord"},{"issue":"3","key":"383_CR14","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1002\/mus.22327","volume":"45","author":"JT Guptill","year":"2012","unstructured":"Guptill JT, Sharma BK, Marano A, Soucy A, Krueger A, Sanders DB. Estimated cost of treating myasthenia gravis in an insured US population. Muscle Nerve. 2012;45(3):363\u20136.","journal-title":"Muscle Nerve"},{"issue":"3","key":"383_CR15","doi-asserted-by":"publisher","first-page":"376","DOI":"10.3988\/jcn.2019.15.3.376","volume":"15","author":"H Xin","year":"2019","unstructured":"Xin H, Harris LA, Aban IB, Cutter G. Examining the impact of refractory myasthenia gravis on healthcare resource utilization in the United States: analysis of a myasthenia gravis foundation of America Patient Registry sample. J Clin Neurol. 2019;15(3):376\u201385.","journal-title":"J Clin Neurol"},{"issue":"7","key":"383_CR16","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1007\/s40273-020-00912-8","volume":"38","author":"E Landfeldt","year":"2020","unstructured":"Landfeldt E, Pogoryelova O, Sejersen T, Zethraeus N, Breiner A, Lochmuller H. Economic costs of myasthenia gravis: a systematic review. Pharmacoeconomics. 2020;38(7):715\u201328.","journal-title":"Pharmacoeconomics"},{"issue":"11","key":"383_CR17","doi-asserted-by":"publisher","first-page":"3063","DOI":"10.1185\/03007990802457040","volume":"24","author":"P Anderson","year":"2008","unstructured":"Anderson P, Benford M, Harris N, Karavali M, Piercy J. Real-world physician and patient behaviour across countries: Disease-Specific Programmes\u2014a means to understand. Curr Med Res Opin. 2008;24(11):3063\u201372.","journal-title":"Curr Med Res Opin"},{"issue":"8","key":"383_CR18","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2015-010352","volume":"6","author":"SM Babineaux","year":"2016","unstructured":"Babineaux SM, Curtis B, Holbrook T, Milligan G, Piercy J. Evidence for validity of a national physician and patient-reported, cross-sectional survey in China and UK: the Disease Specific Programme. BMJ Open. 2016;6(8): e010352.","journal-title":"BMJ Open"},{"key":"383_CR19","doi-asserted-by":"publisher","first-page":"371","DOI":"10.2147\/DMSO.S120101","volume":"9","author":"V Higgins","year":"2016","unstructured":"Higgins V, Piercy J, Roughley A, Milligan G, Leith A, Siddall J, et al. Trends in medication use in patients with type 2 diabetes mellitus: a long-term view of real-world treatment between 2000 and 2015. Diabetes Metab Syndr Obes. 2016;9:371\u201380.","journal-title":"Diabetes Metab Syndr Obes"},{"key":"383_CR20","unstructured":"National Institute of Health. Myasthenia gravis fact sheet. 2020. https:\/\/www.ninds.nih.gov\/Disorders\/Patient-Caregiver-Education\/Fact-Sheets\/Myasthenia-Gravis-Fact-Sheet."},{"key":"383_CR21","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.e8497","volume":"345","author":"J Spillane","year":"2012","unstructured":"Spillane J, Higham E, Kullmann DM. Myasthenia gravis. BMJ Br Med J. 2012;345: e8497.","journal-title":"BMJ Br Med J"},{"key":"383_CR22","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1186\/1471-2377-13-132","volume":"13","author":"A Elsais","year":"2013","unstructured":"Elsais A, Wyller VB, Loge JH, Kerty E. Fatigue in myasthenia gravis: is it more than muscular weakness? BMC Neurol. 2013;13:132.","journal-title":"BMC Neurol"},{"issue":"10","key":"383_CR23","doi-asserted-by":"publisher","DOI":"10.1002\/brb3.538","volume":"6","author":"S Hoffmann","year":"2016","unstructured":"Hoffmann S, Ramm J, Grittner U, Kohler S, Siedler J, Meisel A. Fatigue in myasthenia gravis: risk factors and impact on quality of life. Brain Behav. 2016;6(10): e00538.","journal-title":"Brain Behav"},{"issue":"6","key":"383_CR24","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1002\/mus.25205","volume":"54","author":"JB Andersen","year":"2016","unstructured":"Andersen JB, Gilhus NE, Sanders DB. Factors affecting outcome in myasthenia gravis. Muscle Nerve. 2016;54(6):1041\u20139.","journal-title":"Muscle Nerve"},{"issue":"6","key":"383_CR25","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1007\/s10072-012-1170-2","volume":"33","author":"IZ Basta","year":"2012","unstructured":"Basta IZ, Pekmezovi\u0107 TD, Peri\u0107 SZ, Kisi\u0107-Tepav\u010devi\u0107 DB, Rako\u010devi\u0107-Stojanovi\u0107 VM, Stevi\u0107 ZD, et al. Assessment of health-related quality of life in patients with myasthenia gravis in Belgrade (Serbia). Neurol Sci. 2012;33(6):1375\u201381.","journal-title":"Neurol Sci"},{"key":"383_CR26","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1186\/s12955-015-0298-1","volume":"13","author":"MI Boldingh","year":"2015","unstructured":"Boldingh MI, Dekker L, Maniaol AH, Brunborg C, Lipka AF, Niks EH, et al. An up-date on health-related quality of life in myasthenia gravis\u2014results from population-based cohorts. Health Qual Life Outcomes. 2015;13:115.","journal-title":"Health Qual Life Outcomes"},{"issue":"11","key":"383_CR27","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0206754","volume":"13","author":"A Jeong","year":"2018","unstructured":"Jeong A, Min J-H, Kang YK, Kim J, Choi M, Seok JM, et al. Factors associated with quality of life of people with Myasthenia Gravis. PLoS ONE. 2018;13(11): e0206754.","journal-title":"PLoS ONE"},{"issue":"2","key":"383_CR28","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1002\/mus.23398","volume":"46","author":"M Masuda","year":"2012","unstructured":"Masuda M, Utsugisawa K, Suzuki S, Nagane Y, Kabasawa C, Suzuki Y, et al. The MG-QOL15 Japanese version: validation and associations with clinical factors. Muscle Nerve. 2012;46(2):166\u201373.","journal-title":"Muscle Nerve"},{"key":"383_CR29","unstructured":"The CIE. Final report: The cost to patients and the community of myasthenia gravis. 2013. https:\/\/www.mgaq.org.au\/sites\/default\/files\/2020-02\/CIE_Final_Report.pdf?."},{"key":"383_CR30","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1186\/1477-7525-8-129","volume":"8","author":"S Twork","year":"2010","unstructured":"Twork S, Wiesmeth S, Klewer J, P\u00f6hlau D, Kugler J. Quality of life and life circumstances in German myasthenia gravis patients. Health Qual Life Outcomes. 2010;8:129.","journal-title":"Health Qual Life Outcomes"},{"issue":"7","key":"383_CR31","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1016\/j.nmd.2021.04.002","volume":"31","author":"AM Ruiter","year":"2021","unstructured":"Ruiter AM, Verschuuren JJGM, Tannemaat MR. Prevalence and associated factors of fatigue in autoimmune myasthenia gravis. Neuromuscul Disord. 2021;31(7):612\u201321.","journal-title":"Neuromuscul Disord"},{"key":"383_CR32","doi-asserted-by":"publisher","first-page":"538","DOI":"10.3389\/fneur.2020.00538","volume":"11","author":"D Menon","year":"2020","unstructured":"Menon D, Barnett C, Bril V. Novel treatments in myasthenia gravis. Front Neurol. 2020;11:538.","journal-title":"Front Neurol"},{"issue":"3","key":"383_CR33","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1093\/oncolo\/oyab058","volume":"27","author":"R Copher","year":"2022","unstructured":"Copher R, Kee A, Gerds A. Treatment patterns, health care resource utilization, and cost in patients with myelofibrosis in the United States. Oncologist. 2022;27(3):228\u201335.","journal-title":"Oncologist"},{"issue":"2","key":"383_CR34","doi-asserted-by":"publisher","first-page":"148","DOI":"10.36469\/jheor.2020.16784","volume":"7","author":"NH Fowler","year":"2020","unstructured":"Fowler NH, Chen G, Lim S, Manson S, Ma Q, Li FY. Treatment patterns and health care costs in commercially insured patients with follicular lymphoma. J Health Econ Outcomes Res. 2020;7(2):148\u201357.","journal-title":"J Health Econ Outcomes Res"},{"issue":"2","key":"383_CR35","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1097\/MCG.0000000000001491","volume":"56","author":"M Lu","year":"2022","unstructured":"Lu M, Goodwin B, Vera-Llonch M, Williams J. Disease burden and treatment patterns associated with eosinophilic esophagitis in the United States: a retrospective claims study. J Clin Gastroenterol. 2022;56(2):133\u201340.","journal-title":"J Clin Gastroenterol"},{"issue":"7","key":"383_CR36","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.3390\/jcm10071537","volume":"10","author":"S Sheikh","year":"2021","unstructured":"Sheikh S, Alvi U, Soliven B, Rezania K. Drugs that induce or cause deterioration of myasthenia gravis: an update. J Clin Med. 2021;10(7):1537.","journal-title":"J Clin Med"},{"issue":"11","key":"383_CR37","doi-asserted-by":"publisher","first-page":"e1171","DOI":"10.1212\/WNL.0000000000008903","volume":"94","author":"E Cortes-Vicente","year":"2020","unstructured":"Cortes-Vicente E, Alvarez-Velasco R, Segovia S, Paradas C, Casasnovas C, Guerrero-Sola A, et al. Clinical and therapeutic features of myasthenia gravis in adults based on age at onset. Neurology. 2020;94(11):e1171\u201380.","journal-title":"Neurology"},{"issue":"4","key":"383_CR38","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1159\/000506310","volume":"54","author":"E Guastafierro","year":"2020","unstructured":"Guastafierro E, Tramacere I, Toppo C, Leonardi M, Mantegazza R, Bonanno S, et al. Employment in myasthenia gravis: a systematic literature review and meta-analysis. Neuroepidemiology. 2020;54(4):304\u201312.","journal-title":"Neuroepidemiology"}],"container-title":["Neurology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-022-00383-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40120-022-00383-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-022-00383-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,23]],"date-time":"2022-10-23T00:27:26Z","timestamp":1666484846000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40120-022-00383-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,20]]},"references-count":38,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["383"],"URL":"https:\/\/doi.org\/10.1007\/s40120-022-00383-3","relation":{},"ISSN":["2193-8253","2193-6536"],"issn-type":[{"value":"2193-8253","type":"print"},{"value":"2193-6536","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,20]]},"assertion":[{"value":"1 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 June 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 July 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}